Mural Oncology reported its third quarter 2024 financial results, highlighting the company's ongoing progress in late-stage trials of nemvaleukin alfa and the expected nomination of candidates for IL-18 and IL-12 programs. The company remains on track with its clinical trials and reiterates its guidance on projected cash runway into Q4 2025.

Mural Oncology reported a net loss of $31.6 million for the second quarter of 2024, with cash, cash equivalents, and marketable securities totaling $204.7 million as of June 30, 2024. The company reaffirms its cash runway guidance into the fourth quarter of 2025 and anticipates readouts from nemvaleukin alfa in two late-stage clinical trials in the first half of 2025.

Mural Oncology reported a net loss of $30.9 million for the first quarter of 2024. The company's clinical trials for nemvaleukin alfa remain on track, with data readouts expected in the first half of 2025. Mural Oncology's cash, cash equivalents, and marketable securities were $231.7 million as of March 31, 2024, which is expected to fund operations into the fourth quarter of 2025.

Mural Oncology reported a net loss of $59.5 million for the fourth quarter of 2023. As of December 31, 2023, cash and cash equivalents were $270.9 million. The company expects its cash resources to fund operations into the fourth quarter of 2025.